A truncated and dimeric format of an Affibody library on bacteria enables FACS-mediated isolation of amyloid-beta aggregation inhibitors with subnanomolar affinity

Biotechnology Journal

Volumn 10, Issue 11, 2015, Pages 1707-1718

  Lindberg, Hanna ^a   Härd, Torleif ^b   Löfblom, John ^a   Ståhl, Stefan ^a  

^a ALBANOVA UNIVERSITY CENTER   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Affibody molecules; Affinity maturation; Amyloid beta; Bacterial display; Combinatorial protein engineering

Indexed keywords

BINDERS; BIOCHEMICAL ENGINEERING; ESCHERICHIA COLI; GENETIC ENGINEERING; GLYCOPROTEINS; LIBRARIES; MOLECULES; NEURODEGENERATIVE DISEASES; PEPTIDES; SCAFFOLDS (BIOLOGY);

AFFIBODY MOLECULES; AFFINITY MATURATION; AGGREGATION INHIBITORS; ALZHEIMER'S DISEASE; AMYLOID BETAS; INTERACTION MECHANISMS; PROTEIN ENGINEERING; STRUCTURAL REARRANGEMENT;

PROTEINS;

AMYLOID BETA PROTEIN; BACTERIUM LYSATE; HYBRID PROTEIN; PEPTIDE LIBRARY; PROTEIN BINDING;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BACTERIAL CELL; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; DNA LIBRARY; ESCHERICHIA COLI; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IN VIVO STUDY; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ENGINEERING; PROTEIN ISOLATION; PROTEIN PROCESSING; STAPHYLOCOCCUS; ANTAGONISTS AND INHIBITORS; CELL SURFACE DISPLAY; CHEMISTRY; COMBINATORIAL CHEMISTRY; METABOLISM; MOLECULAR MODEL; PROCEDURES;

AMYLOID BETA-PEPTIDES; CELL SURFACE DISPLAY TECHNIQUES; COMBINATORIAL CHEMISTRY TECHNIQUES; ESCHERICHIA COLI; FLOW CYTOMETRY; MODELS, MOLECULAR; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; STAPHYLOCOCCUS;

EID: 84947041962     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201500131     Document Type: Article

References (50)

1. Hall, A. M., Roberson, E. D., Mouse models of Alzheimer's disease. Brain Res. Bull. 2012, 88, 3-12.
2. Hardy, J., Selkoe, D. J., The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
3. Galimberti, D., Scarpini, E., Treatment of Alzheimer's disease: Symptomatic and disease-modifying approaches. Curr. Aging Sci. 2010, 3, 46-56.
4. Citron, M., Alzheimer's disease: Strategies for disease modification. Nat. Rev. Drug Discovery 2010, 9, 387-398.
5. Walsh, D. M. and Selkoe, D. J., A Oligomers-a decade of discovery. J. Neurochem. 2007, 101, 1172-1184.
6. Arimon, M., Díez-Pérez, I., Kogan, M. J., Durany, N. et al., Fine structure study of Abeta1-42 fibrillogenesis with atomic force microscopy. FASEB J. 2005, 19, 1344-1346.
7. Hard, T., Lendel, C., Inhibition of amyloid formation. J. Mol. Biol. 2012, 421, 441-465.
8. Robert, R., Wark, K. L., Engineered antibody approaches for Alzheimer's disease immunotherapy. Arch. Biochem. Biophys. 2012, 526, 132-138.
9. Demattos, R. B., Lu, J., Tang, Y., Racke, M. M. et al., A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron 2012, 76, 908-920.
10. Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D. et al., Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. N atl. Acad. Sci. U.S.A. 2012, 109, 3510-3515.
11. Weiner, H. L., Frenkel, D., Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 2006, 6, 404-416.
12. Frenkel, D., Solomon, B., Towards Alzheimer's beta-amyloid vaccination. Biologicals 2001, 29, 243-247.
13. Wilcock, D. M., Rojiani, A., Rosenthal, A., Levkowitz, G. et al., Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 2004, 24, 6144-6151.
14. Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D. et al., Monoclonal antibodies against b-amyloid (Aβ) for the treatment of Alzheimer's disease: The Aβ target at a crossroads. Expert Opin. Biol. Ther. 2011, 11, 679-686.
15. Salloway, S. S. R., Gilman, S., Fox, N. C., Blennow, K. et al., A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73, 2061-2070.
16. Nisbet, R. M., Nigro, J., Breheney, K., Caine, J. et al., Central amyloid-beta-specific single chain variable fragment ameliorates Abeta aggregation and neurotoxicity. Protein Eng. Des. Sel. 2013, 26, 571-580.
17. Lofblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J. et al., Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010, 584, 2670-2680.
18. Malm, M., Bass, T., Gudmundsdotter, L., Lord, M. et al., Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension. Biotechnol. J. 2014, 9, 1215-1222.
19. Orlova, A., Jonsson, A., Rosik, D., Lundqvist, H. et al., Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. J. Nucl. Med. 2013, 54, 961-968.
20. Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K. et al., Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci. Transl. Med. 2014, 6, 261ra154.
21. Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K. et al., Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 2011, 3, 84ra44.
22. Sorensen, J., Sandberg, D., Sandstrom, M., Wennborg, A. et al., First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J. Nucl. Med. 2014, 55, 730-735.
23. Löfblom, J., Frejd, F. Y., Ståhl, S., Non-immunoglobulin based protein scaffolds. Curr. Opin. Biotechnol. 2011, 22, 843-848.
24. Gronwall, C., Jonsson, A., Lindstrom, S., Gunneriusson, E. et al., Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. J. Biotechnol. 2007, 128, 162-183.
25. Hoyer, W., Gronwall, C., Jonsson, A., Stahl, S., Hard, T., Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 5099-5104.
26. Lindgren, J., Wahlstrom, A., Danielsson, J., Markova, N. et al., N-terminal engineering of amyloid-beta-binding Affibody molecules yields improved chemical synthesis and higher binding affinity. Protein Sci. 2010, 19, 2319-2329.
27. Hoyer, W. and Hard, T., Interaction of Alzheimer's A beta peptide with an engineered binding protein - thermodynamics and kinetics of coupled folding-binding. J. Mol. Biol. 2008, 378, 398-411.
28. Luheshi, L. M., Hoyer, W., de Barros, T. P., van Dijk Hard, I. et al., Sequestration of the Abeta peptide prevents toxicity and promotes degradation in vivo. PLoS Biol. 2010, 8, e1000334.
29. Moreth, J., Mavoungou, C., Schindowski, K., Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. Front. Aging Neurosci. 2013, 5, 25.
30. Pesaresi, M., Lovati, C., Bertora, P., Mailland, E. et al., Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 2006, 27, 904-905.
31. Du, C., Ramaley, C., McLean, H., Leonard, S. C., Miller, J., High-performance liquid chromatography coupled with tandem mass spectrometry for the detection of amyloid beta peptide related with Alzheimer's disease. J. Biomol. Tech. 2005, 16, 354-361.
32. Kuo, Y. M., Kokjohn, T. A., Kalback, W., Luehrs, D. et al., Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma. Biochem. Biophys. Res. Commun. 2000, 268, 750-756.
33. Lichtlen, P., Mohajeri, M. H., Antibody-based approaches in Alzheimer's research: Safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem. 2008, 104, 859-874.
34. Pesini, P., Pérez-Grijalba, V., Monleón, I., Boada, M. et al., Reliable measurements of the b-amyloid pool in blood could help in the early diagnosis of AD. Int. J. Alzheimer's Dis. 2012, 2012, 604141.
35. Lofblom, J., Bacterial display in combinatorial protein engineering. Biotechnol. J. 2011, 6, 1115-1129.
36. Lofblom, J., Wernerus, H., Stahl, S., Fine affinity discrimination by normalized fluorescence activated cell sorting in staphylococcal surface display. FEMS Microbiol. Lett. 2005, 248, 189-198.
37. Fleetwood, F., Devoogdt, N., Pellis, M., Wernery, U. et al., Surface display of a single-domain antibody library on Gram-positive bacteria. Cell Mol. Life Sci. 2013, 70, 1081-1093.
38. Kronqvist, N., Lofblom, J., Jonsson, A., Wernerus, H., Stahl, S., A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Protein Eng. Des. Sel. 2008, 21, 247-255.
39. Malm, M., Kronqvist, N., Lindberg, H., Gudmundsdotter, L. et al., Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One 2013, 8, e62791.
40. Lindberg, H., Johansson, A., Hard, T., Stahl, S., Lofblom, J., Staphylococcal display for combinatorial protein engineering of a head-to-tail affibody dimer binding the Alzheimer amyloid-beta peptide. Biotechnol. J. 2013, 8, 139-145.
41. Lofblom, J., Kronqvist, N., Uhlen, M., Stahl, S., Wernerus, H., Optimization of electroporation-mediated transformation: Staphylococcus carnosus as model organism. J. Appl. Microbiol. 2007, 102, 736-747.
42. Jonsson, A., Dogan, J., Herne, N., Abrahmsen, L., Nygren, P. A., Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng. Des. Sel. 2008, 21, 515-527.
43. Guex, N., Peitsch, M. C., SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 1997, 18, 2714-2723.
44. Scott, W. R. P., Hünenberger, P. H., Tironi, I. G., Mark, A. E. et al., The GROMOS Biomolecular Simulation Package. J. Phys. Chem. A 1999, 103, 3596-3607.
45. Andersen, J. T., Pehrson, R., Tolmachev, V., Daba, M. B. et al., Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J. Biol. Chem. 2011, 286, 5234-5241.
46. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C. et al., Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 8850-8855.
47. Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L. et al., A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci. Transl. Med. 2011, 3, 84ra43.
48. Citron, M., Strategies for disease modification in Alzheimer's disease. Nat. Rev. Neurosci. 2004, 5, 677-685.
49. Zlokovic, B. V., The blood-brain barrier in health and chronic neurodegenerative disorders Neuron 2008, 57, 178-201.
50. Pan, W. K. A. J., Changing the chemokine gradient: CINC1 crosses the blood-brain barrier. J. Neuroimmunol. 2001, 115, 64-70.